TSX runs higher on rate cut expectations
Lantheus Holdings Inc . (NASDAQ:LNTH) stock has reached a 52-week low, touching down at $74.92. This price level reflects a notable dip for the company, which specializes in diagnostic imaging and targeted therapeutics. According to InvestingPro analysis, the company maintains excellent financial health with a "GREAT" overall rating and robust liquidity, demonstrated by a current ratio of 5.74. Despite the current low, over the past year, Lantheus Holdings has experienced a decrease of 4.9% in its stock value. Investors are closely monitoring the company’s performance, considering the broader market trends and the firm’s strategic moves to gauge the potential for recovery or further decline. InvestingPro analysis suggests the stock is currently undervalued, with analysts maintaining a strong buy consensus. Discover more insights and 12 additional ProTips in the comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, Lantheus Holdings reported its Q1 2025 financial results, revealing a shortfall in both earnings per share (EPS) and revenue compared to analyst estimates. The company’s EPS was $1.53, falling short of the expected $1.64, while revenue reached $372.8 million, missing the forecasted $377.79 million. Despite these setbacks, Lantheus provided a revenue guidance range of $1.55 billion to $1.585 billion for 2025, with an adjusted EPS guidance of $6.60 to $6.70. The company anticipates double-digit revenue growth in 2026, driven by potential product launches and a focus on PET diagnostics and radiotherapeutics.
Additionally, Lantheus has been active in strategic acquisitions, having announced plans to acquire Evergreen Theranostics and Life Molecular Imaging to bolster its radiopharmaceutical capabilities. The company also revealed plans to divest its SPECT business to Shine Technologies. Truist Securities adjusted its outlook on Lantheus, reducing the price target to $117 from $127 but maintained a Buy rating, citing the company’s growth potential despite a slight miss in PYL sales. These developments reflect Lantheus’ ongoing efforts to diversify its revenue streams and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.